Research Topic: Combination therapy

Characterizing antimicrobial activity of environmental Streptomyces spp. and oral bacterial and fungal isolates from Canis familiaris and Felis catus

mycolabadmin

Researchers collected bacteria and fungi from the mouths of pet dogs and cats, as well as environmental soil bacteria, to search for natural antimicrobial compounds. They found that some of these microorganisms produce substances that can kill harmful bacteria like E. coli and fungi like Candida albicans, especially when combined with existing antifungal medications. Notably, one environmental bacterium (Streptomyces) produced a compound that was even effective against fungal strains resistant to common antifungal drugs, suggesting promising new treatment possibilities.

Read More »

Recent innovations and challenges in the treatment of fungal infections

mycolabadmin

Fungal infections are becoming more common and harder to treat due to drug resistance, especially in people with weakened immune systems. Current antifungal medications are becoming less effective because fungi are adapting to resist them, and these drugs can cause serious side effects. Scientists are developing new treatment strategies using combinations of existing drugs, engineered biological approaches, and specially designed delivery systems to overcome resistance and improve patient outcomes.

Read More »

The mycelium of the Trametes versicolor synn. Coriolus versicolor (Turkey tail mushroom) exhibit anti-melanoma activity in vitro

mycolabadmin

Turkey tail mushrooms, used in traditional Chinese medicine for thousands of years, show promise in fighting melanoma skin cancer. Scientists tested mushroom extracts on melanoma cells in the laboratory and found they kill cancer cells through multiple mechanisms, including triggering programmed cell death and activating the immune system. The mushroom extract also reduced cancer cell migration and showed potential to work better when combined with standard chemotherapy drugs like paclitaxel. These findings suggest turkey tail could be a valuable addition to melanoma treatment strategies.

Read More »

Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies

mycolabadmin

This editorial highlights the growing problem of fungal infections that resist current treatments, causing millions of deaths worldwide each year. Researchers are finding new ways to fight these resistant infections by repurposing existing drugs in new combinations and discovering novel compounds from natural sources. The collection of studies presented shows promising results using combinations like minocycline with antifungal drugs, natural compounds like baicalin, and AI technology to predict resistance patterns. These innovative approaches offer hope for better treatment options for patients suffering from serious fungal infections.

Read More »

Synergistic effects of Cyp51 isozyme-specific azole antifungal agents on fungi with multiple cyp51 isozyme genes

mycolabadmin

This study found that different azole antifungal drugs work better against different versions of an enzyme (Cyp51) that fungi need to survive. By combining two azole drugs that each target different enzyme versions, researchers achieved stronger antifungal effects than either drug alone. This discovery suggests a new strategy for treating stubborn fungal infections by carefully selecting drug combinations based on which enzyme versions the fungus possesses.

Read More »

Antifungal Activity of Selected Naphthoquinones and Their Synergistic Combination with Amphotericin B Against Cryptococcus neoformans H99

mycolabadmin

Scientists tested five synthetic compounds called naphthoquinones to see if they could fight a serious fungal infection called cryptococcosis. They found that one compound called 2-MNQ worked well against the fungus and was even more effective when combined with a standard antifungal drug (amphotericin B). The combination was strong enough to potentially allow lower doses of the existing drug, which could reduce side effects while improving treatment outcomes.

Read More »

The Ptk2-Pma1 pathway enhances tolerance to terbinafine in Trichophyton rubrum

mycolabadmin

Researchers discovered that a protein called TrPtk2 helps dermatophytes resist terbinafine, a common antifungal medicine. They found that blocking this protein makes the fungus more susceptible to terbinafine. Additionally, they discovered that omeprazole, a stomach medication approved for human use, can be combined with terbinafine to make it more effective against resistant fungal infections.

Read More »
Scroll to Top